Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Lane Hall-Witt who wrote (79026)	1/14/2000 9:54:00 AM
From: Mr. Stress	Respond to of 120523

Anyone think it might be time to buy CPQ?

To: Lane Hall-Witt who wrote (79026)	1/14/2000 9:56:00 AM
From: kha vu	Respond to of 120523

CELL, BWEB,PVSW are good to watch for a few weeks period. CDTS is another one that can be daytraded. Good trading

To: Lane Hall-Witt who wrote (79026)	1/14/2000 1:18:00 PM
From: kha vu	Respond to of 120523

GZSP: <<<Stock of the Day Jan 14, 2000 Genzyme Surgical: A Value-Laden Biotech Director of Online Research: Dave Sterman (1/14/00) Biotech stocks are back in vogue. Take a look at the Nasdaq Biotech index, which rose from 587 in early November to a recent 948—a 61% jump in less than three months! But not all biotech stocks were asked to dance at the party. Little-known Genzyme Surgical Products (NASDAQ:GZSP - news) was pretty much a wallflower most of last fall, although when the New Year came around, the shares rose a few points, thanks to new coverage from one sell-side analyst, Hambrecht & Quist's Chris Shibutani. Otherwise, the stock remains off the radar. From early October through January 6, the shares languished in the $4 to $5 range. Then on Friday, January 7, the stock rallied to $8.13. On Thursday, the stock closed at $8. The reasons for the company's relative anonymity are quite simple. It was partially spun off last June from Genzyme Corp. (NASDAQ:GENZ - news) with little fanfare. While the parent company, Genzyme, is one of the biggest healthcare companies around, the spun-off Genzyme Surgical is something of a hybrid that may be suffering because of its mix of medical devices and biotechnologies. >>>> fnews.yahoo.com